Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter‐2: Human midbrain dopamine neurons
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The dopaminergic neurons in the ventral substantia nigra (SN) are significantly more vulnerable to degeneration in Parkinson's disease (PD) than the dopaminergic neurons in the ventral tegmental area (VTA). The ventral SN neurons also contain significantly more neuromelanin pigment than the dopaminergic neurons in the VTA. In vitro data indicate that neuromelanin pigment is formed from the excess cytosolic catecholamine that is not accumulated into synaptic vesicles by the vesicular monoamine transporter‐2 (VMAT2). By using quantitative immunohistochemical methods in human postmortem brain, we sought to examine the relative contents of VMAT2 within neurons that contain different amounts of neuromelanin pigment. The immunostaining intensity (ISI) was measured for VMAT2 and also for the rate‐limiting enzyme for the synthesis of dopamine, tyrosine hydroxylase (TH). ISI measures were taken from the ventral SN region where neurons are most vulnerable to degeneration in PD, nigrosome‐1 (N1); from the ventral SN region where cells are moderately vulnerable to degeneration in PD, the matrix (M); and from VTA neurons near the exit of the third nerve (subregion III). The data indicate that 1) subregion III neurons have significantly higher levels of VMAT2 ISI compared with N1 neurons (more than twofold) and M neurons (45%); 2) there is an inverse relationship between VMAT2 ISI and neuromelanin pigment in the N1 and III neurons; 3) there is an inverse relationship between VMAT2 ISI and the vulnerability to degeneration in PD in the N1, M, and III subregions; and 4) neurons with high VMAT2 ISI also have high TH ISI. These data support the hypothesis that midbrain dopaminergic neurons that synthesize greater amounts of dopamine have more vesicular storage capacity for action potential‐induced release of transmitter and that the ventral SN neurons accumulate the most neuromelanin pigment, in part because they have the least VMAT2 protein. J. Comp. Neurol. 473:97–106, 2004. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301 · cited 1×
“Furthermore, NM pigment has been shown to bind neurotoxins such as 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP; D’Amato et al., 1987) and paraquat (Lindquist et al., 1988), which could serve as a “toxin pool” within the catecholaminergic neurons.”
BackgroundMacromolecular crowding: an important but neglected aspect of the intracellular environment
Ellis, R. J. (2001) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(00)00172-x · Cited by 1,153
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126 · cited 1×
“NM pigment could be toxic to aminergic neurons insofar as it physically interferes with intracellular communication (Graham, 1978; Mann and Yates, 1983), causing a “macromolecular crowding” effect (Ellis, 2001), thereby interfering with the synthesis and degradation of cellular proteins.”
Background
Cited by
Dopamine: Functions, Signaling, and Association with Neurological Diseases
Klein, M. O., Battagello, D. S., Cardoso, A. R., Hauser, D. N., Bittencourt, J. C., & Correa, R. G. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0632-3 · Cited by 1,073
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
“…and degraded, so that reactive iron (Zecca et al., 2008a; Zhang et al., 2011) and other toxins previously accumulated by NM (D’Amato et al., 1986; Karlsson and Lindquist, 2013; Lindquist et al., 1988; Ostergren et al., 2004; Salazar et al., 1978) are suddenly released and can cause cell death.”
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease
Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 587
Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.033 · Cited by 534
Neuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25095 · Cited by 315
Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Sulzer, D., Cassidy, C., Horga, G., Kang, U. J., Fahn, S., Casella, L., Pezzoli, G., Langley, J., Hu, X. P., Zucca, F. A., et al. (2018) · npj Parkinson's Disease · doi:10.1038/s41531-018-0047-3 · Cited by 270
Norepinephrine: The redheaded stepchild of Parkinson's disease
Rommelfanger, K. S., & Weinshenker, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.036 · Cited by 255
Neuromelanin of the Human Substantia Nigra: An Update
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243
Zecca, L., Bellei, C., Costi, P., Albertini, A., Monzani, E., Casella, L., Gallorini, M., Bergamaschi, L., Moscatelli, A., Turro, N. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808768105 · Cited by 240
“It has been suggested that neuromelanin synthesis protects the neurons in the substantia nigra because it removes neurotoxic quinones (7, 8).”
BackgroundNeuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25187 · Cited by 184
Influences of dopaminergic system dysfunction on late-life depression
Taylor, W. D., Zald, D. H., Felger, J. C., Christman, S., Claassen, D. O., Horga, G., Miller, J. M., Gifford, K., Rogers, B., Szymkowicz, S. M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01265-0 · Cited by 89
The pathology roadmap in Parkinson disease
Surmeier, D. J., & Sulzer, D. (2013) · Prion · doi:10.4161/pri.23582 · Cited by 74
Zucca, F. A., Capucciati, A., Bellei, C., Sarna, M., Sarna, T., Monzani, E., Casella, L., & Zecca, L. (2023) · IUBMB Life · doi:10.1002/iub.2654 · Cited by 69
“Indeed, regions like ventral tegmental area (VTA), SN pars reticulata and SN pars compacta, in the mentioned order, have increasing content of NM and increasing neuronal vulnerability, while VMAT2 expression is decreasing from VTA to SN pars reticulata and pars compacta.(24) In principle, the 56 ZUCCA ET AL.”
Background
Metadata
- Authors
- Liang, C., Nelson, O., Yazdani, U., Pasbakhsh, P., & German, D. C.
- Venue
- Journal of Comparative Neurology
- Publisher
- Wiley
- Published
- 2004-03-30
- Volume
- 473
- Issue
- 1
- Pages
- 97-106
- ISSN
- 0021-9967 (ISSN-L)
- 1096-9861
- OpenAlex
- W2024098527
- Cited by
- 117
- References
- 4
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.